Revenue grew 4% year-over-year in Q1 2025, but net loss widened due to higher R&D expenses and unrealized investment losses. Gross margin improved to 48%, and the board approved new employee stock options post-quarter.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.